FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 英諾賽科（ 蘇州）科技股份有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02577 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股 ...

InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 完成根據一般授權配售新H股 及 修訂《公司章程》 獨家整體協調人 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據1933年美國證券法（經修訂）登記 或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將僅以 招股章程的方式進行，該招股章程可向發行人或出售證券持有人取得，並載有發行人及管理層 的詳細資料 ...

Core Viewpoint - InnoCare (stock code: 2577) announced a financing plan through the placement of new H shares, aiming to raise approximately HKD 550 million, with net proceeds expected to be around HKD 540 million after expenses [1] Group 1: Financing Details - The company plans to issue 13,584,000 new H shares at a placement price of HKD 40.50, representing a discount of about 8.9% compared to the previous trading day's closing price of HKD 44.45 [1] - The placement price also reflects a discount of approximately 3.0% compared to the average closing price over the last five trading days [1] - The new shares will account for approximately 1.54% of the existing issued share capital and about 1.52% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 270 million of the proceeds will be allocated for product upgrades and the development of new application technologies [1] - Around HKD 140 million will be used to repay existing interest-bearing bank debts [1] - Another HKD 140 million is designated for working capital and general operational purposes [1] Group 3: Completion Timeline - The issuance is expected to be completed on the first trading day after the fulfillment or waiver of placement conditions, but no later than five days after the placement agreement date or another date agreed upon in writing with the placement agent [1]

Core Viewpoint - InnoCare (02577.HK) has entered into a placement agreement to issue 13.584 million new H-shares at a price of HKD 40.50 per share, aiming to raise approximately HKD 550 million to enhance its financial strength and market competitiveness [1] Group 1: Placement Details - The placement shares represent about 2.77% of the total issued H-shares and approximately 1.54% of the total issued shares as of the announcement date [1] - The estimated total amount raised from the placement, assuming full subscription, is expected to be HKD 550 million, with a net amount of approximately HKD 544 million after deducting commissions and estimated expenses [1] Group 2: Use of Proceeds - Approximately 50% of the funds will be used to support product upgrades and technology research and development to enhance the competitiveness of GaN products [2] - About 25% of the funds will be allocated to repay existing interest-bearing bank debts, improving the company's financial condition and reducing financial expenses [2] - The remaining 25% will be used to supplement working capital and for general operational purposes, including talent recruitment and administrative expenses [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據1933年美國證券法（經修訂）登記 或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將僅以 招股章程的方式進行，該招股章程可向發行人或出售證券持有人取得，並載有發行人及管理層 的詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 根據一般授 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 變更聯席公司秘書 聯席公司秘書辭任 英諾賽科（蘇州）科技股份有限公司（「本公司」）董事會（「董事會」）近日收到劉麗 華女士的辭任申請，因工作變動原因，劉麗華女士辭去本公司之聯席公司秘書職 務，劉麗華女士之辭任自2025年7月18日（即取得香港聯合交易所有限公司（「香 港聯交所」）豁免公司秘書資格的批准之日）起生效。 劉麗華女士確認其與董事會之間並無意見分歧，亦無其他有關辭任之事宜需敦請 本公司股東加以垂注。劉麗華女士在擔任聯席公司秘書期間，勤勉盡責，恪盡職 守。董事會對劉麗華女士做出的重要貢獻表示衷心的感謝。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英諾賽科 ( 蘇 州 ) 科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 余先生及鍾先生的簡歷詳情如下： 余曉桐先生，1990年7月出生，中國籍。余先生現任本公 ...

Company Overview - InnoScience (英诺赛科) is a high-tech enterprise focused on the research and manufacturing of GaN-on-Si (Gallium Nitride on Silicon) devices, utilizing an Integrated Device Manufacture (IDM) model [2] - The company has established the world's largest 8-inch GaN-on-Si wafer production line, aiming to provide high-quality and reliable GaN devices at lower prices [2] Financial Performance - As of December 31, 2024, InnoScience reported total revenue of 828 million yuan, representing a year-on-year growth of 39.77% [1] - The net profit attributable to shareholders was -1.046 billion yuan, with a year-on-year increase of 5.11% [1] - The gross profit margin stood at -19.48%, and the debt-to-asset ratio was 46.44% [1] Stock Performance - As of July 16, the stock price of InnoScience was 41.85 HKD per share, with a daily increase of 9.55% and a trading volume of 7.3499 million shares, amounting to a turnover of 298 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 3.24%, while year-to-date, it has risen by 22.24%, underperforming the Hang Seng Index, which has increased by 22.58% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the semiconductor industry (TTM) is 26.15 times, with a median of 7.36 times [1] - InnoScience's P/E ratio is -29.8 times, ranking 15th in the industry [1] - Comparatively, other companies in the sector have the following P/E ratios: China Electric Power Technology (4.77), AV CONCEPT HOLD (6.77), Yuanxu Technology (7.36), Chipwise Holdings (8.33), and Jingyang Group (11.53) [1]

Group 1 - The Hang Seng Index rose by 0.28%, gaining 68 points to close at 24,658 points, while the Hang Seng Tech Index increased by 0.61% [1] - The Hong Kong stock market saw a trading volume of HKD 157.9 billion in the morning session [1] - The National Healthcare Security Administration of China added innovative commercial insurance drugs to the list for 2025, supporting new drugs with high clinical value but payment bottlenecks, leading to a rise in the Hang Seng Biotechnology Index [1] Group 2 - Livzon Pharmaceutical (01513) surged by 12.69% as the Phase II clinical trial for its cardiovascular innovative drug H001 capsule completed patient enrollment [2] - InnoCare Pharma (02577) increased by 6.41%, planning to significantly enhance its 8-inch gallium nitride wafer production capacity over the next five years [2] - China Heartland Fertilizer (01866) rose by 3.83% following reports of a meeting held by relevant authorities to ensure the supply and stabilize prices of potash fertilizer [2] Group 3 - Chongqing Machinery and Electric (02722) saw a significant increase of over 17% due to catalysts in the domestic AIDC market, with Chongqing Cummins being a supplier for engines [2] Group 4 - Jifang Zhitu Holdings (09636) rose by 10.18% after announcing a proposed share placement to raise approximately HKD 746 million for developing on-chain financial resources [3] Group 5 - Smoore International (06969) fell by 3.55%, expecting a year-on-year decline of approximately 21% to 35% in half-year profits [4] - Kanglong Chemical (03759) issued a profit warning, dropping by 5.24%, with an expected year-on-year decline of 36% to 39% in net profit attributable to shareholders for the first half [5]

Core Viewpoint - The article highlights significant stock movements in the Hong Kong and US markets, indicating various companies experiencing notable gains due to specific events or developments. Hong Kong Market Highlights - Li Auto (02015) saw a rise of over 3% as the launch of the Li i8 is set for July 29 [1] - Chinese banks experienced gains, with Zhengzhou Bank (06196) up 6.06%, Minsheng Bank (01988) up 4.97%, CITIC Bank (00998) up 3.24%, and Industrial and Commercial Bank of China (01398) up 1.8% [1] - Jiuyuan Gene (02566) increased by over 6% following the approval of its drug by the National Medical Products Administration [1] - Conant Optical (02276) rose over 6% as its net profit is expected to increase by over 30% year-on-year [1] - Puxing Energy (00090) surged over 220% after acquiring equity in HashKey Holdings Limited, entering the digital asset finance sector [1] - Blucube (00325) saw a rise of over 8% as it faced its first share unlock, with an accelerated pace of new product launches [1] - InnoCare Pharma (02577) rose over 5% as TSMC exited the GaN business, prompting cornerstone investors to extend their lock-up period [2] - Jitu Express (01519) increased over 4% due to strong package volume performance in Southeast Asia [2] - Apple-related stocks saw gains, with Cowell (01478) up 5.14%, Sunny Optical (02382) up 4.99%, BYD Electronics (00285) up 4.67%, and AAC Technologies (02018) up 1.89% [2] - From Yuzhi Agriculture (00875) surged over 13% as the company aims to build a comprehensive modern agriculture flagship group [2] - Fenbi (02469) rose over 5% following an upgrade to its AI question-answering system, which is expected to drive performance growth [2] - E-Surfing (02550) increased over 16% after Barclays acquired a 280 million stake and partnered with Huawei Cloud [2] - Cryptocurrency ETF and related stocks rose, with New Fire Technology Holdings (01611) up 10.82%, Xiong'an Technology (01647) up 10.23%, and others [2] - Superstar Legend (06683) surged over 20% as Jay Chou joined Douyin, gaining over 10 million followers [3] - Cornerstone Pharmaceuticals (02616) rose over 4% after its drug production application was approved by NMPA [3] - Longguang Group (03380) opened over 4% higher as its debt restructuring plan was approved by creditors [3] - Saijing Technology (00580) opened over 8% after announcing a projected net profit of approximately 90 million, a 167% year-on-year increase [3] - Derin Holdings (01709) opened nearly 15% higher as it plans to tokenize up to 500 million HKD in assets for distribution to shareholders [3] US Market Highlights - Deutsche Bank (DB.US) rose over 3% as it restructures its wealth management business in Germany to improve profitability [4] - UnitedHealth (UNH.US) fell over 1% amid reports of a US Department of Justice investigation into its medical insurance billing [4] - Futu Holdings (FUTU.US) increased over 9% after Morgan Stanley raised its target price to 160 USD [4] - Boeing (BA.US) rose over 3% as June aircraft deliveries reached an 18-month high [4] - Meta (META.US) increased nearly 2% as it reportedly invested 3.5 billion USD to enhance its AI smart glasses business [4] - Nvidia (NVDA.US) rose nearly 2%, reaching a historic high with a market capitalization of 4 trillion USD [4] - Microsoft (MSFT.US) hit a historic high with a market capitalization of 3.74 trillion USD, following an upgrade from Oppenheimer [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 茲提述英諾賽科（蘇州）科技股份有限公司（「本公司」）日期為2025年6月19日有關 本公司2025年第一次臨時股東會（「臨時股東會」）通函（「通函」）及臨時股東會通 告。除另有界定者外，本公告所用詞彙與通函所界定者具有相同涵義。 臨時股東會已於2025年7月9日（星期三）於中國江蘇省蘇州市吳江區黎里鎮北厙新 黎路98號研發大樓9樓會議室順利舉行。臨時股東會的召開程序符合中國相關法 規及本公司組織章程的規定，表決結果合法有效。 臨時股東會出席情況 於臨時股東會日期，已發行股份總數為880,816,653股股份（包括389,559,466股境 內未上市股份及491,257,187股H ...